Key result
In patients undergoing off-pump coronary bypass surgery with recent antiplatelet therapy, the use of HES 200/0.5 or HES 130/0.4 did not significantly increase perioperative blood loss or transfusion requirements compared to crystalloid solutions.
Why the study?
Do hydroxyethyl starch (HES) 200/0.5 and 130/0.4 solutions affect blood loss and transfusion requirement compared to crystalloid solutions in patients with recent antiplatelet therapy undergoing off-pump coronary bypass surgery?
RCT (n=60)
Single-blind
Randomly allocated
No
Do hydroxyethyl starch (HES) 200/0.5 and 130/0.4 solutions affect blood loss and transfusion requirement compared to crystalloid solutions in patients with recent antiplatelet therapy undergoing off-pump coronary bypass surgery?
Supports HES as alternative volume expander in off-pump CABG with recent antiplatelet therapy; extends RCT safety data in this population.
Background: Hydroxyethylstarch (HES) solutions are commonly used for intravascular volume expansion with varying effect on coagulation depending on molecular weight and mode of hydroxyl substitution. Clopidogrel and aspirin have been shown to reduce cardiovascular complications in patients with coronaryartery occlusive disease which renders patients to higher risk of bleeding complications who require surgery. The purpose of this study was to evaluate the effect of HES 200/0.5, 130/0.4 and crystalloid on blood loss and transfusion requirement in patients with recent antiplatelet therapy undergoing off-pump coronary bypass surgery (OPCAB) in a prospective, randomized trial.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2008) conducted an RCT in Coronary artery occlusive disease requiring off-pump coronary bypass surgery (OPCAB) with recent antiplatelet therapy (n=60). Hydroxyethyl starch (HES) 200/0.5 and HES 130/0.4 vs. Crystalloid solution was evaluated on Amount of perioperative blood loss and transfusion requirement (p=>0.05). In patients undergoing off-pump coronary bypass surgery with recent antiplatelet therapy, the use of HES 200/0.5 or HES 130/0.4 did not significantly increase perioperative blood loss or transfusion requirements compared to crystalloid solutions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: